Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Lixte Biotech Hlds (LIXT)

Lixte Biotech Hlds (LIXT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,573
  • Shares Outstanding, K 13,663
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,260 K
  • 60-Month Beta -1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.11
Trade LIXT with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.62 +4.96%
on 07/27/21
3.57 -22.96%
on 07/13/21
-0.28 (-9.24%)
since 06/30/21
3-Month
2.51 +9.78%
on 05/04/21
3.70 -25.68%
on 05/19/21
-0.01 (-0.36%)
since 04/30/21
52-Week
2.36 +16.53%
on 04/20/21
7.86 -65.01%
on 09/10/20
-4.33 (-61.16%)
since 07/30/20

Most Recent Stories

More News
LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM

LixteBiotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer treatments, commented on pre-clinical research demonstrating...

LIXT : 2.75 (-2.31%)
Lixte Biotechnology Comments on Outside Research Citing LB-100's PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) ("Lixte" or the "Company") noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine's Cancer Biology...

LIXT : 2.75 (-2.31%)
Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021

Presentation to highlight Company's current clinical study of lead compound LB-100 for Small Cell Lung Cancer

LIXT : 2.75 (-2.31%)
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

-- Due to the aggressive progression of small cell lung cancer, it is possible that therapeutic benefit in patients may be seen in this early-stage clinical trial

LIXT : 2.75 (-2.31%)
Sidoti Microcap Virtual Conference

SCAN.VN : 0.670 (unch)
MDP.VN : 7.750 (-4.91%)
SOLR.VN : 0.225 (-2.17%)
MEDXF : 5.8850 (+0.42%)
GLVMF : 5.2110 (-1.49%)
NTSFF : 0.5664 (+6.51%)
UGEIF : 1.2700 (+2.42%)
LDDFF : 0.5376 (-0.20%)
LXR.TO : 0.1000 (unch)
PANL : 4.71 (-3.48%)
POETF : 0.8950 (+4.80%)
TNYYF : 1.0100 (+2.54%)
URG : 1.1300 (-8.13%)
DBD : 10.41 (-2.80%)
GENTF : 54.9400 (-7.20%)
BDI.TO : 4.05 (+1.00%)
SLNG : 8.04 (-3.01%)
STRR : 3.60 (-5.01%)
VNRX : 3.18 (+0.95%)
ALOT : 16.05 (+4.63%)
JRSH : 7.15 (-1.33%)
DHX : 4.00 (+1.52%)
TREC : 7.92 (+0.38%)
MINM : 2.50 (unch)
ARHH : 1.7900 (unch)
GAIA : 11.91 (-0.75%)
GSIT : 5.49 (+2.43%)
HIL : 2.16 (-4.85%)
MKGI : 2.27 (+7.08%)
OSS : 5.99 (+13.23%)
VERB : 2.33 (-2.51%)
ABML : 1.5700 (-1.87%)
CVEO : 21.71 (-0.69%)
ISUN : 9.24 (+0.87%)
LIXT : 2.75 (-2.31%)
TESS : 6.01 (+0.17%)
WSTG : 28.35 (+0.85%)
APEN : 8.09 (+10.07%)
CTG : 8.91 (-0.89%)
EML : 29.36 (-0.41%)
ACU : 42.30 (+0.87%)
AMST : 2.08 (-0.95%)
BSET : 22.78 (-2.48%)
BKEPP : 8.20 (-0.36%)
BKEP : 3.43 (-3.92%)
EFOI : 3.74 (-1.84%)
FLXS : 34.50 (-3.06%)
MDCA : 5.61 (-1.75%)
OBLG : 2.60 (-2.62%)
PCTI : 6.65 (+1.53%)
SAMG : 15.96 (+1.53%)
VQS.TO : 7.89 (-10.85%)
CVGI : 9.14 (-1.30%)
ORN : 5.37 (-3.76%)
WLMS : 4.93 (+1.23%)
LXU : 8.80 (+5.52%)
LCUT : 15.07 (-0.53%)
LINC : 6.94 (-0.29%)
STRT : 41.18 (-2.80%)
GVP : 1.4100 (+0.71%)
LMB : 8.92 (-1.98%)
AFI : 4.32 (-2.70%)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS

Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as an independent director and audit committee chair.

LIXT : 2.75 (-2.31%)
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20

Multiple pre-clinical studies indicate that Lixte's lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments

LIXT : 2.75 (-2.31%)
Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14

-- Lixte's pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100

LIXT : 2.75 (-2.31%)
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors

Lixte Biotechnology Holdings, Inc. ("Lixte" or the "Company") (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, announced the...

LIXT : 2.75 (-2.31%)
Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual Benzinga...

LIXT : 2.75 (-2.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Lixte Biotechnology Holdings Inc. is a drug discovery company which uses biomarker technology to identify enzyme targets associated with serious common diseases. The company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents...

See More

Key Turning Points

3rd Resistance Point 3.35
2nd Resistance Point 3.23
1st Resistance Point 2.99
Last Price 2.75
1st Support Level 2.62
2nd Support Level 2.50
3rd Support Level 2.26

See More

52-Week High 7.86
Fibonacci 61.8% 5.76
Fibonacci 50% 5.11
Fibonacci 38.2% 4.46
Last Price 2.75
52-Week Low 2.36

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar